mitigating-the-risk-of-low-quality-data-for-commercial-pharma

WHITE PAPER

Mitigating the Risks of Low-Quality Data for Commercial Pharma

Real-world data (RWD) is central to today’s commercial pharma playbook—from pre-launch planning to ongoing prescriber engagement. But low-quality data can sabotage your strategy from the start. Inaccurate NPIs, fragmented patient tokens, and synthetic records inflate your market size, misguide HCP targeting, and waste marketing spend.

In this white paper, HealthVerity exposes the hidden risks of this low-quality “zombie data” and explains how legacy tokenization errors lead to flawed forecasts, inflated costs per physician, and regulatory risks. You’ll discover how Verified Data delivers higher fidelity, reduced waste, and stronger commercial performance.

Download our white paper to learn:

  • What “zombie data” is and how it distorts real-world analytics
  • How poor patient tokenization inflates prescriber counts and marketing costs
  • Why flawed data sabotages AI models and compliance efforts
  • How Verified Data improves targeting accuracy, campaign ROI, and audit readiness